After expenses, CuraGen will receive approximately $12 million in cash.
Timothy Shannon, president and CEO of CuraGen, said: “We also retain further potential upside related to belinostat consisting of up to $6 million in potential milestone payments on future net sales and sublicenses of belinostat.”